INTERVENTION 1:	Intervention	0
MK-0752	Intervention	1
Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days	Intervention	2
inhibitor	CHEBI:35222	21-30
drug	CHEBI:23888	31-35
MK-0752: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.	Intervention	3
letrozole	CHEBI:6413	52-61
letrozole	CHEBI:6413	172-181
mouth	UBERON:0000165	72-77
time	PATO:0000165	82-86
time	PATO:0000165	222-226
day	UO:0000033	91-94
day	UO:0000033	102-105
day	UO:0000033	231-234
day	UO:0000033	254-257
day	UO:0000033	272-275
day	UO:0000033	290-293
day	UO:0000033	405-408
day	UO:0000033	428-431
day	UO:0000033	445-448
day	UO:0000033	497-500
contraindication	OAE:0000055	152-168
tamoxifen	CHEBI:41774	195-204
inhibitor	CHEBI:35222	352-361
drug	CHEBI:23888	362-366
Inclusion Criteria:	Eligibility	0
Patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory, and is not metastatic. - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy.	Eligibility	1
breast cancer	DOID:1612	113-126
size	PATO:0000117	186-190
Patients must not have bilateral tumors. Tumor must be amenable to core biopsy in midstudy.	Eligibility	2
bilateral	HP:0012832	23-32
Patients must be >18 years of age.	Eligibility	3
age	PATO:0000011	30-33
Patients must have a performance status 1 by Zubrod criteria.	Eligibility	4
Patients must have a life expectancy of greater than three months.	Eligibility	5
Patients must have normal organ and marrow function within 28 days of registration as defined below:	Eligibility	6
organ	UBERON:0000062	26-31
function	BAO:0003117,BFO:0000034	43-51
absolute neutrophil count >1,500/μL	Eligibility	7
platelets >100,000/μL	Eligibility	8
total bilirubin 1.5 x the institutional upper limit of normal	Eligibility	9
x	LABO:0000148	20-21
AST(SGOT)/ALT(SGPT) <2 X institutional upper limit of normal	Eligibility	10
x	LABO:0000148	23-24
creatinine within normal institutional limits OR	Eligibility	11
creatinine	CHEBI:16737	0-10
creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal	Eligibility	12
creatinine clearance	CMO:0000765	0-20
m2	CHEBI:34827	37-39
creatinine	CHEBI:16737	0-10
creatinine	CHEBI:16737	58-68
Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. A negative serum pregnancy test must be obtained within 72 hours of receiving the first dose of the hormonal therapy as well as within 72 hours of the first dose of the MK-0752 GSI medication for women of child-bearing potential. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.	Eligibility	13
duration	PATO:0001309	165-173
Exclusion Criteria:	Eligibility	14
Patients may not have received any prior chemotherapy or endocrine therapy (tamoxifen, raloxifene, or an aromatase inhibitor) and may not have received prior therapy with a gamma-secretase inhibitor or other investigational agents. - Patients may not have received previous radiation therapy.	Eligibility	15
tamoxifen	CHEBI:41774	76-85
raloxifene	CHEBI:8772	87-97
inhibitor	CHEBI:35222	115-124
inhibitor	CHEBI:35222	189-198
Patients may not be currently participating or have participated in a study with an investigational compound or device within 30 days.	Eligibility	16
Patients must not have known brain or CNS disease, evidence of brain or CNS metastases, or carcinomatous meningitis.	Eligibility	17
brain	UBERON:0000955	29-34
brain	UBERON:0000955	63-68
disease	DOID:4,OGMS:0000031	42-49
meningitis	HP:0001287,DOID:9471	105-115
Patients must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.	Eligibility	18
active	PATO:0002354	102-108
congestive heart failure	HP:0001635,DOID:6000	132-156
angina pectoris	HP:0001681	167-182
arrhythmia	HP:0011675	192-202
Patients may not have known hypersensitivity to the components of MK-0752 or it analogs.	Eligibility	19
hypersensitivity	GO:0002524,DOID:1205	28-44
Patients will be excluded if there is a known history of human immunodeficiency (HIV) virus infection, or a known history of hepatitis B or C infection.	Eligibility	20
excluded	HP:0040285	17-25
history	BFO:0000182	46-53
history	BFO:0000182	114-121
immunodeficiency	HP:0002721	63-79
virus	BAO:0000232	86-91
hepatitis b	DOID:2043	125-136
Patients must not have a previous history of inflammatory bowel disease or uncontrolled irritable bowel syndrome.	Eligibility	21
history	BFO:0000182	34-41
inflammatory bowel disease	DOID:0050589	45-71
irritable bowel syndrome	DOID:9778	88-112
Patients must not have a history of greater than one basal cell carcinoma of the skin within the past five years or a history of Gorlin syndrome.	Eligibility	22
history	BFO:0000182	25-32
history	BFO:0000182	118-125
basal cell carcinoma	HP:0002671,DOID:2513	53-73
syndrome	DOID:225	136-144
Outcome Measurement:	Results	0
Number of Participants Experiencing at Least One Adverse Event	Results	1
adverse event	OAE:0000001	49-62
The number of participants experiencing at least one adverse event during the 24-day observation period and initial post-operative visit.	Results	2
adverse event	OAE:0000001	53-66
Time frame: 30 days	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: MK-0752	Results	5
Arm/Group Description: Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days	Results	6
inhibitor	CHEBI:35222	44-53
drug	CHEBI:23888	54-58
MK-0752: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.	Results	7
letrozole	CHEBI:6413	52-61
letrozole	CHEBI:6413	172-181
mouth	UBERON:0000165	72-77
time	PATO:0000165	82-86
time	PATO:0000165	222-226
day	UO:0000033	91-94
day	UO:0000033	102-105
day	UO:0000033	231-234
day	UO:0000033	254-257
day	UO:0000033	272-275
day	UO:0000033	290-293
day	UO:0000033	405-408
day	UO:0000033	428-431
day	UO:0000033	445-448
day	UO:0000033	497-500
contraindication	OAE:0000055	152-168
tamoxifen	CHEBI:41774	195-204
inhibitor	CHEBI:35222	352-361
drug	CHEBI:23888	362-366
Overall Number of Participants Analyzed: 20	Results	8
Measure Type: Count of Participants	Results	9
Unit of Measure: Participants  At least one adverse event: 15  75.0%	Results	10
adverse event	OAE:0000001	44-57
No Adverse Events: 5  25.0%	Results	11
Adverse Events 1:	Adverse Events	0
Total: 0/20 (0.00%)	Adverse Events	1
